ESG Report 2023

Inner Mongolia Company Successfully Completed the On-site Inspection for EU-GMP In the Year, the German Ministry of Justice and Consumer Protection conducted a three-day re-inspection of the production and quality control of Inner Mongolia Company. This successful EU-GMP on-site inspection demonstrates that the company's GMP management level continuously meets the standards of EU-GMP, providing opportunities for the company to compete in the fiercely competitive European market and laying a solid foundation for its rapid development. We adhere to the international advanced GMP standards for pharmaceutical production quality control, pursue international development, and our products have successively obtained export country GMP certification inspections, obtaining access to international markets. In the European market, the certification of sterile active pharmaceutical ingredients such as Amoxicillin Sodium is another successful inspection, following multiple EU-GMP inspections and European Directorate for the Quality of Medicines (EDQM) inspections since 2011, for both newly certified production lines and previously certified production lines. Additionally, non-sterile active pharmaceutical ingredients such as Amoxicillin and Ampicillin have continuously passed EU member states' GMP certification inspections since 2006. EU-GMP certification has significant influence globally and is regarded as a "passport" for pharmaceutical products to enter international markets. EU member states mutually recognize and share the results of GMP inspections, and these results are also shared with countries such as Japan, the United States, Australia, and Canada. Obtaining EU-GMP certification is a reliable recognition of a pharmaceutical company's production capabilities and product quality. 39 Environmental, Social and Governance Report 2023 The United Laboratories International Holdings Limited